Results

Immutep Ltd.

11/09/2022 | Press release | Distributed by Public on 11/08/2022 23:18

Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination